AiCure

Seattle Genetics

Seattle Genetics, Genmab enter into antibody-drug conjugate collaboration

Thursday, September 11, 2014 01:20 PM

Seattle Genetics, a biotech company focused on development and commercialization of innovative antibody-based therapies for cancer, and Genmab, a Denmark-based international biotech company specializing in differentiated human antibody therapeutics for cancer, have entered into an additional antibody-drug conjugate (ADC) collaboration.

More... »


Seattle Genetics, Agensys to co-develop ADC

Wednesday, July 3, 2013 09:30 AM

Seattle Genetics has exercised an option to co-develop an additional antibody-drug conjugate (ADC) under an existing ADC collaboration agreement with Agensys, an affiliate of Tokyo-based Astellas Pharma. The ADC, called ASG-15ME, targets the tumor antigen SLITRK6, which is expressed on bladder and lung cancer.

More... »


Seattle Genetics, Bayer in ADC collaboration

Wednesday, June 26, 2013 03:13 PM

Biotech Seattle Genetics has entered into an antibody-drug conjugate (ADC) collaboration with Bayer HealthCare. Bayer will pay upfront and option exercise fees of up to $20 million for worldwide rights to utilize Seattle Genetics' auristatin-based ADC technology with antibodies to several oncology targets. Seattle Genetics also is eligible to receive up to $500 million in potential milestone payments, as well as royalties on worldwide net sales of any resulting products under the multi-target collaboration. Bayer is responsible for research, product development, manufacturing and commercialization of all products. 

More... »

Blaze Bioscience raises $9.8M in Series A financing

Monday, February 25, 2013 10:28 AM

Blaze Bioscience, a Seattle-based biotechnology company focused on cancer, has completed a Series A financing totaling $8.5 million, bringing the total funds raised since inception to $9.8 million.

More... »

Icon, DIA to deliver new educational product

Monday, February 11, 2013 09:53 AM

Icon,a global provider of outsourced development, has formed a collaboration with DIA, a neutral, global, professional, member-driven association of nearly 18,000 pharmaceutical, biotechnology, and medical device professionals, to deliver the first solution-provider webinar, which offers free access to knowledge and innovative solutions to overcome some of the key challenges in medical product development.

More... »

Seattle Genetics, Abbott expand antibody-drug conjugate collaboration

Wednesday, October 24, 2012 11:02 AM

Seattle Genetics, a Bothell, Wash.-based biotech focused on monoclonal antibody-based therapies for the treatment of cancer, has expanded its antibody-drug conjugate (ADC) collaboration with Abbott Laboratories, a global healthcare company.

More... »

Seattle Genetics, Millennium, Ventana collaborate on companion diagnostic test for Adcetris

Friday, April 13, 2012 12:37 PM

Seattle Genetics and Millennium, a subsidiary of Takeda Pharmaceutical, have formed a collaboration with Ventana Medical Systems, a member of the Roche Group, through which Ventana will seek to develop, manufacture and commercialize a molecular companion diagnostic test with the goal of identifying patients who might respond to treatment with Adcetris based on CD30 expression levels in their tissue specimens.

More... »

Interim data released on phase I Adcetris trial

Friday, January 27, 2012 02:01 PM

Seattle Genetics and Millennium, the Takeda oncology company, released interim results from 32 patients treated to date in a phase I clinical trial of Adcetris (brentuximab vedotin) administered in combination or sequentially with chemotherapy for the treatment of newly diagnosed systemic anaplastic large cell lymphoma (sALCL) and other CD30-positive mature T-cell lymphoma patients.

More... »

Seattle Genetics, Abbott collaborate

Wednesday, March 23, 2011 12:08 PM

Abbott will pay an upfront fee of $8 million for rights to utilize Seattle Genetics' antibody-drug conjugate (ADC) technology with antibodies to a single oncology target.

More... »

Millennium expands cancer pact with Seattle Genetics

Friday, March 18, 2011 01:43 PM

Takeda's Millennium has expanded its antibody-drug conjugate deal with Seattle Genetics, paying an undisclosed fee to exercise an option to designate a second antigen target outlined in their 2009 collaboration, according to Biosmart.

More... »

CenterWatch Data Library
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

November 24

Tufts CSDD’s $2.6 billion price tag to develop and bring a new drug to market raises questions, criticisms

Medidata joins GlaxoSmithKline in study to evaluate the impact of wearing mobile devices in clinical trials

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

November

Private equity driving dynamic CRO growth
Enables CROs to pursue long-term strategies, while giving the space credibility

Baby boomers poised to reshape clinical trials industry
Millions of tech-savvy consumers already track their health, expect new treatments as they age

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

October

CROs driving changes in patient recruitment
Data- and tech-aided enrollment services a competitive advantage

Trials with in-home nurses poised to grow
Higher expense, but may improve recruitment and retention for select trials

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs